NF-κB–driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance

Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors harboring an activated mutation on EGFR; however, up to 40% of lung cancer patients exhibit acquired resistance to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Proc Natl Acad Sci U S A
Main Authors: Chiu, Ching-Feng, Chang, Yi-Wen, Kuo, Kuang-Tai, Shen, Yu-Shiuan, Liu, Chien-Ying, Yu, Yang-Hao, Cheng, Ching-Chia, Lee, Kang-Yun, Chen, Feng-Chi, Hsu, Min-Kung, Kuo, Tsang-Chih, Ma, Jui-Ti, Su, Jen-Liang
Formato: Artigo
Idioma:Inglês
Publicado em: National Academy of Sciences 2016
Assuntos:
PNAS Plus
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4983816/
https://ncbi.nlm.nih.gov/pubmed/27091996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1522612113
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados